SCHEMBL3860359

SCHEMBL3860359

COC(=O)c1cnc2ccc(OC)nc2c1

nearest known ligand 0.51

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.51
ALDH1A1 P00352 1/20 0.51
PSMD14 O00487 1/20 0.48
HPGD P15428 4/20 0.47
ALOX15 P16050 1/20 0.46
HTT P42858 1/20 0.46
MAPK1 P28482 2/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
NNMT P40261 1/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HPGDS O60760 3/20 0.42
ATM Q13315 1/20 0.41
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL622212 0.86 MGAM (0.49) KDM4EALDH1A1PSMD14HPGDL3MBTL1
SCHEMBL621881 0.86 NPC1 (0.57) KDM4EALDH1A1HPGDHTTL3MBTL1
SCHEMBL22074907 0.85 PSMD14 (0.48) KDM4EALDH1A1PSMD14HPGDALOX15
SCHEMBL28647317 0.83 PSMD14 (0.49) KDM4EALDH1A1PSMD14HPGDALOX15
SCHEMBL26009759 0.82 PSMD14 (0.48) KDM4EALDH1A1PSMD14HPGDALOX15
SCHEMBL22074963 0.82 PSMD14 (0.48) KDM4EALDH1A1PSMD14HPGDALOX15
SCHEMBL22075282 0.79 PSMD14 (0.46) KDM4EALDH1A1PSMD14HPGDALOX15
SCHEMBL10466162 0.78 HTT (0.67) KDM4EALDH1A1PSMD14HPGDALOX15
SCHEMBL14783630 0.77 TDP1 (0.54) KDM4EALDH1A1HPGDHTTMAPK1
SCHEMBL30134289 0.77 HPGD (0.46) ALDH1A1HPGDNNMTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8071592-B2 Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones GLAXO GROUP LIMITED (GB) 2011-12-06 US disclosed
US-20090270374-A1 DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
EP-2044077-A1 DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES Glaxo Group Limited (GB) 2009-04-08 EP disclosed
EP-1992628-A1 Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones GLAXO GROUP LIMITED (GB) 2008-11-19 EP disclosed
WO-2008009700-A1 DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES GLAXO GROUP LIMITED (GB) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270374-A1 DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES ETFA, NQO2, GNAQ KDM4E 2078/4885ALDH1A1 3885/4885PSMD14 1683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.